ACELYRIN, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 13th, 2023 • ACELYRIN, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 13th, 2023 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of September, 2022, by and among ACELYRIN, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION BY AND AMONG ACELYRIN, INC., WH1, INC., WH2, LLC, VALENZABIO, INC., AND SHAREHOLDER REPRESENTATIVE SERVICES LLC Dated as of December 20, 2022Merger Agreement • April 13th, 2023 • ACELYRIN, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 13th, 2023 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (as amended, restated, supplemented or otherwise modified from time to time in accordance with the terms herewith, this “Agreement”) is made and entered into as of December 20, 2022 (the “Agreement Date”), by and among: (i) ACELYRIN, INC., a Delaware corporation (“Parent”); (ii) WH1, Inc., a Delaware corporation and a wholly owned, direct subsidiary of Parent (“First Merger Sub”); (iii) WH2, LLC, a Delaware limited liability company and a wholly owned, direct subsidiary of Parent (“Second Merger Sub” and with First Merger Sub, each a “Merger Sub” and together, the “Merger Subs”); (iv) ValenzaBio, Inc., a Delaware corporation (the “Company”); and (v) solely in its capacity as the representative of the Sellers, Shareholder Representative Services LLC, a Colorado limited liability company (the “Seller Representative”). Capitalized terms used herein have the meanings ascribed thereto in Article I or elsewhere in this Agreement as identif
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • April 13th, 2023 • ACELYRIN, Inc. • Pharmaceutical preparations
Contract Type FiledApril 13th, 2023 Company IndustryTHIS LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of March 25, 2021 (“Effective Date”) is entered into between Pierre Fabre Medicament SAS, a company duly organized and existing under the laws of France, having offices and principal place of business at 45, Place Abel Gance 92100 Boulogne Billancourt, France (“Licensor”) and ValenzaBio Inc., a limited liability company organized under the laws of Delaware and having its principal place of business at 6701 Democracy Blvd, Suite 300, Bethesda, MD 20817 (“Licensee”).
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • April 13th, 2023 • ACELYRIN, Inc. • Pharmaceutical preparations
Contract Type FiledApril 13th, 2023 Company IndustryTHIS LICENSE AND COLLABORATION AGREEMENT (the “Agreement”), entered into as of August 9, 2021 (the “Effective Date”), by and between Affibody AB, a Swedish company with registration no. 556665-6913, with a principal place of business at Scheeles väg 2, SE-171 65 Solna, Sweden (“Affibody”) and ACELYRIN, INC., a Delaware corporation with a principal place of business at 23371 Mulholland Dr., PMB 417, Woodland Hills, CA 91364 (“ACELYRIN”, and collectively with Affibody, the “Parties” and each, a “Party”).